0I0X.LSE Codexis Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -125.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0I0X.LSE undervalued?
Graham numberThe Graham number of Codexis Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Codexis Inc. fundamental analysis
No fundamental analysis for Codexis Inc. yet.
Codexis Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Codexis Inc.
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic rou…
Full company profileCodexis Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Codexis Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 48.8M | 50.0M | 60.6M | 68.5M | 69.1M | 105M | 139M | 70.1M | 59.3M | 70.4M | 60.3M |
| Gross Profit | 39.1M | 34.7M | 46.8M | 51.0M | 53.4M | 79.4M | 95.2M | -1.55M | 38.2M | 61.0M | 44.3M |
| Operating Income | -8.56M | -23.0M | -11.3M | -12.5M | -23.9M | -22.7M | -31.7M | -68.1M | -58.4M | -38.3M | -38.5M |
| EBITDA | -4.02M | -21.9M | -10.1M | -7.15M | -19.1M | -15.1M | -23.1M | -66.2M | -57.1M | -30.0M | -29.8M |
| Net Income | -8.56M | -23.0M | -10.9M | -11.9M | -24.0M | -21.3M | -33.6M | -76.2M | -65.3M | -44.0M | -41.4M |
| EPS | -0.21 | -0.50 | -0.21 | -0.21 | -0.40 | -0.33 | -0.51 | -1.12 | -0.89 | -0.50 | -0.45 |
| Balance Sheet | |||||||||||
| Total Assets | 35.6M | 53.6M | 79.3M | 149M | 222M | 246M | 250M | 137M | 149M | 148M | 120M |
| Total Liabilities | 16.5M | 29.1M | 23.0M | 43.6M | 51.5M | 82.0M | 106M | 49.9M | 82.1M | 97.3M | 87.1M |
| Shareholders' Equity | 19.1M | 24.5M | 56.3M | 106M | 170M | 164M | 145M | 86.6M | 66.9M | 50.5M | 33.0M |
| Cash & Short-term Investments | 19.2M | 31.2M | 53.0M | 91.2M | 151M | 117M | 115M | 65.1M | 74.0M | 78.7M | 55.3M |
| Total Debt | 425K | 302K | 61.0K | 32.6M | 25.0M | 57.6M | 45.2M | 17.0M | 59.9M | 73.2M | 72.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.86M | -8.76M | -14.1M | -12.6M | -16.5M | -14.3M | 11.3M | -52.6M | -49.4M | -19.4M | -45.6M |
| Capital Expenditure | 888K | 985K | 2.77M | 3.73M | 3.75M | 13.8M | 8.31M | 4.42M | 4.31M | 4.47M | 2.15M |
| Free Cash Flow | -2.75M | -9.74M | -16.9M | -16.3M | -20.2M | -28.1M | 2.98M | -57.1M | -53.7M | -23.8M | -47.7M |
| Ratios | |||||||||||
| ROE | -44.8% | -93.7% | -19.3% | -11.3% | -14.1% | -12.9% | -23.2% | -88.0% | -97.5% | -87.0% | -125.7% |
| ROA | -24.0% | -42.9% | -13.7% | -8.0% | -10.8% | -8.6% | -13.4% | -55.8% | -43.8% | -29.8% | -34.5% |
| Net Profit Margin | -17.5% | -46.0% | -18.0% | -17.4% | -34.8% | -20.3% | -24.2% | -108.7% | -110.0% | -62.5% | -68.7% |
| Debt to Equity | 0.02x | 0.01x | 0.00x | 0.31x | 0.15x | 0.35x | 0.31x | 0.20x | 0.89x | 1.45x | 2.20x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Codexis Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 1.26M | 0.02 | - |
| 2019 | USD 2.85M | 0.05 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Codexis Inc.
- Insiders 7.11%
- Institutions 73.91%
- Public & others 18.99%
- Free float 82.3M
Codexis Inc. company profile
- Company name
- Codexis Inc.
- Ticker
- 0I0X.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 146
- Fiscal year end
- December
- Address
- 200 Penobscot Drive, Redwood City, CA, United States, 94063
- Phone
- 650 421 8100
- Website
- codexis.com
About Codexis Inc.
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Codexis Inc. management
6- Dr. Alison Moore Ph.D.President, CEO & Director · born 1967
- Ms. Georgia L. ErbezCFO & Chief Business Officer · born 1967
- Dr. Stefan Lutz Ph.D.Chief Scientific Officer
- Mr. Britton JimenezSenior Vice President of Sales & Marketing
- Ms. Karen Frechou-ArmijoSenior VP & Head of Human Resources
- Mr. John SchiffhauerSenior Vice President of Intellectual Property